<DOC>
	<DOCNO>NCT00925132</DOCNO>
	<brief_summary>The purpose study treat metastatic melanoma combination standard chemotherapy ( decitabine Temozolomide dose escalation scheme ) study drug call panobinostat . This combination propose unlock gene may contribute mechanism cause tumor growth . The primary objective study : - To evaluate safety tolerability propose schedule decitabine , temozolomide panobinostat treatment metastatic melanoma . - To define Dose Limiting Toxicity ( DLT ) maximum tolerate dose ( MTD ) combination decitabine , temozolomide panobinostat .</brief_summary>
	<brief_title>Treatment Resistant Metastatic Melanoma Using Decitabine , Temozolomide Panobinostat</brief_title>
	<detailed_description>Most chemotherapeutics target rapidly proliferate cell , leave quiescent cell extend cell cycle unaffected . The investigator propose combination decitabine , temozolomide , panobinostat target melanoma stem cell rapidly proliferate melanoma cell . The use two drug regulate gene expression epigenetically ( panobinostat decitabine ) combination chemotherapeutic agent ( temozolomide ) hypothesize : - induce expression gene ( e.g. , Apaf-1 ) increase chemosensitivity tumor cell enhance apoptosis - potentiate cytotoxic effect temozolomide epigenetic modulation , - induce proliferation differentiation tumor stem cell , thus enable senescence apoptosis . Secondary objective : - To measure overall survival - To measure time progression patient treat combination comparison patient treat historically DTIC ( current standard care ) . - To evaluate treatment response FDG PET compare FDG PET conventional image treatment response assessment .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Male female patient age ≥ 18 year old 2 . ECOG Performance Status ≤ 2 3 . Ability provide write informed consent obtain prior participation study relate procedure perform 4 . Patients must measurable disease accord RECIST CHOI criterion . The minimum targetlesion diameter double CT slice thickness , i.e. , 10 mm 5 . Patients must meet follow laboratory criterion : Hematology : Neutrophil count &gt; 1500/mm3 ; Platelet count &gt; 100,000/mm3L ; Hemoglobin ≥ 9 g/dL Biochemistry : AST/SGOT ALT/SGPT ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x upper limit normal transaminase elevation due disease involvement ; Serum bilirubin ≤ 1.5 x upper limit normal ; Serum creatinine ≤ 1.5 x upper limit normal 24hour creatinine clearance ≥ 50 ml/min ; Total serum calcium ( correct serum albumin ) ionize calcium ≥ low limit normal ; Serum potassium ≥ low limit normal ; Serum sodium ≥ low limit normal ; Serum albumin ≥ low limit normal 3g/dl ; Patients elevate alkaline phosphatase due bone metastasis enrol 6 . Baseline ECHO must demonstrate LVEF ≥ low limit institutional normal . 7 . TSH free T4 within normal limit ( patient may thyroid hormone replacement ) 8 . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 8 day first administration study treatment must willing use two method contraception one barrier method study 3 month last study drug administration 9 . Any patient diagnosis metastatic melanoma site . These include untreated patient treat chemotherapy biochemotherapy . 10 . Must take hypomethylating agent histone deacetylase agent treatment disease . Patients receive target agent would need 2week washout period . 11 . Any patient metastatic melanoma regardless prior treatment eligible . 12 . Patients must disease progression follow recent treatment regimen presentation first time metastatic disease , surgical option entertain localized relapse . 13 . Patients CNS disease eligible treatment CNS disease directly address radiation therapy . 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer 2 . Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment 3 . Impaired cardiac function include one following : Screening ECG QTc &gt; 450 msec confirm central laboratory prior enrollment study ; Patients congenital long QT syndrome ; History sustain ventricular tachycardia ; Any history ventricular fibrillation torsades de pointes ; Bradycardia define heart rate &lt; 50 beat per minute . Patients pacemaker heart rate ≥ 50 beat per minute eligible ; Patients myocardial infarction unstable angina within 6 month study entry ; Congestive heart failure ( NY Heart Association class III IV ) ; Right bundle branch block leave anterior hemiblock ( bifascicular block ) 4 . Uncontrolled hypertension 5 . Concomitant use drug risk cause torsades de pointes 6 . Concomitant use CYP3A4 inhibitor 7 . Patients unresolved diarrhea &gt; CTCAE grade 1 8 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat 9 . Other concurrent severe and/or uncontrolled medical condition 10 . Patients receive chemotherapy , investigational drug undergone major surgery &lt; 4 week prior start study drug recover side effect therapy . 11 . Concomitant use anticancer therapy radiation therapy . 12 . Patients measurable disease . 13 . Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 8 day first administration oral panobinostat . 14 . Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom 15 . Patients history another primary malignancy within 5 year curatively treat CIS cervix , basal squamous cell carcinoma skin 16 . Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require 17 . Patients significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Epigenetic</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589</keyword>
</DOC>